Article citationsMore>>

Menzies, A.M., Johnson, D.B., Ramanujam, S., et al. (2017) Anti-PD-1 Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity with Ipilimumab. Annals of Oncology, 28, 368-376.
https://doi.org/10.1093/annonc/mdw443

has been cited by the following article:

• TITLE: PD-1/PD-L1 Signaling Pathway and Tumor Immune Escape

  AUTHORS: Zhenqi Xu, Wei Du

  KEYWORDS: Programmed Death 1, Programmed Death Ligand 1, Neoplasms, Immunotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 9, 2023

  ABSTRACT: PD-1 and its ligands PD-L1 and PD-L2 are widely expressed on the surface of a variety of cells and are a group of costimulatory molecules related to negative immune regulation. The activation of the PD-1/PD-L1 signaling pathway is beneficial for tumors to escape from immune surveillance, but the specific tumor immune escape mechanism is not yet clear. As far as the efficacy of anti-PD-1 and anti-PD-L1 antibodies is concerned, more in-depth research on tumor immune escape mechanisms is still needed. The article summarizes these findings to provide ideas for antitumor immunotherapy.